Latest Conference Coverage

The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.

The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.

Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

The FDA authorized the natural killer cell therapy combo for compassionate use.

Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.

Of the 8 treated patients who were evaluable, 6 patients had stable disease at Day 28.

Based on the findings, investigators are considering registration with the FDA and EMA.

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

Among the 31 patients evaluable for efficacy analysis, ORR was 100%.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.

BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.

The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.

The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.

The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.

Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.

The associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.

Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the foundation’s mission.

The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.

A second cohort has been dosed with 7.7e11 vg/kg to hopefully confirm the dose for phase 3 trials.

The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.

The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.

The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.

The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.